UCLA Department of Bioengineering

bioeng.ucla.edu

The most exciting science in the 21st century is likely to evolve among, not within, traditional disciplines. Around the world, Bioengineering has begun to establish itself as an independent field and engineering discipline, at the boundary between biology and the physical sciences. UCLA and the faculty of bioengineering have embraced this critical and unique opportunity to make a rapid significant impact in the field with an innovative curriculum, state-of-the-art facilities, and cutting-edge research.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

BIOGEN AND GINKGO BIOWORKS COLLABORATE AND LICENSE AGREEMENT TO DEVELOP NOVEL GENE THERAPY MANUFACTURING PLATFORM

Biogen, Ginkgo Bioworks | May 22, 2021

news image

Biogen and Ginkgo Bioworks announced a partnership in gene therapy today. The companies aim to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors by working together. Recombinant AAV-based vectors are extensively used in the development of novel gene therapies with the ability to cure neurological and neuromuscular diseases, as well as other conditions in a variety of therapeutic areas. Manufacturing is now time-consuming and ex...

Read More

Industrial Impact

PDS BIOTECH ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA AND PREPARATION FOR THE REGISTRATIONAL TRIAL

PDS Biotechnology | October 04, 2022

news image

PDS Biotechnology Corporation a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® for the treatment of unresectable, recurrent/metastatic human papilloma virus 16-positive head and neck squamous cell carcinoma. Read More

Medical

THERMO FISHER SCIENTIFIC AND QATAR GENOME PROGRAM PARTNER TO ADVANCE PRECISION MEDICINE

Thermo Fisher Scientific | May 24, 2022

news image

Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally. Under the agreement, Thermo Fisher and Qatar Genome Program will develop an Axiom* custom genotyping array for pan-Arab populations using w...

Read More

MedTech

BENCHLING IS EXPANDING INTO THE EARLY DEVELOPMENT MARKET TO ACCELERATE THE CREATION OF BREAKTHROUGH PRODUCTS

Benchling | September 17, 2021

news image

Benchling , innovator of the research and development (R&D) cloud for the biotechnology industry, today announced its entry into the early development market. The company brings new solutions to market that enable scientists for the first time to work seamlessly from research to development in a single system. By expanding the range of services, the Benchling R&D cloud is designed to offer both the flexibility and speed required for research efficiency as well as the control and conformi...

Read More
news image

Cell and Gene Therapy

BIOGEN AND GINKGO BIOWORKS COLLABORATE AND LICENSE AGREEMENT TO DEVELOP NOVEL GENE THERAPY MANUFACTURING PLATFORM

Biogen, Ginkgo Bioworks | May 22, 2021

Biogen and Ginkgo Bioworks announced a partnership in gene therapy today. The companies aim to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors by working together. Recombinant AAV-based vectors are extensively used in the development of novel gene therapies with the ability to cure neurological and neuromuscular diseases, as well as other conditions in a variety of therapeutic areas. Manufacturing is now time-consuming and ex...

Read More
news image

Industrial Impact

PDS BIOTECH ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA AND PREPARATION FOR THE REGISTRATIONAL TRIAL

PDS Biotechnology | October 04, 2022

PDS Biotechnology Corporation a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® for the treatment of unresectable, recurrent/metastatic human papilloma virus 16-positive head and neck squamous cell carcinoma. Read More

news image

Medical

THERMO FISHER SCIENTIFIC AND QATAR GENOME PROGRAM PARTNER TO ADVANCE PRECISION MEDICINE

Thermo Fisher Scientific | May 24, 2022

Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally. Under the agreement, Thermo Fisher and Qatar Genome Program will develop an Axiom* custom genotyping array for pan-Arab populations using w...

Read More
news image

MedTech

BENCHLING IS EXPANDING INTO THE EARLY DEVELOPMENT MARKET TO ACCELERATE THE CREATION OF BREAKTHROUGH PRODUCTS

Benchling | September 17, 2021

Benchling , innovator of the research and development (R&D) cloud for the biotechnology industry, today announced its entry into the early development market. The company brings new solutions to market that enable scientists for the first time to work seamlessly from research to development in a single system. By expanding the range of services, the Benchling R&D cloud is designed to offer both the flexibility and speed required for research efficiency as well as the control and conformi...

Read More